Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| KYMR | PRESS-RELEASE | neutral | 4/10 | Kymera Therapeutics announced that KT-621 Phase 1b atopic dermatitis data will be presented at SID and ATS conferences, | May 15, 2026 |
| TARA | PRESS-RELEASE | bullish | 7/10 | Protara Therapeutics announced positive updated 12-month data from its Phase 2 ADVANCED-2 trial of TARA-002 in BCG-Naïve | May 15, 2026 |
| TLX | PRESS-RELEASE | neutral | 4/10 | Telix announced non-binding letters of intent to collaborate with EDAP TMS and Profound Medical, exploring the use of it | May 15, 2026 |
| SPRY | PRESS-RELEASE | bearish | 6/10 | ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M, beating the $22.1M consensus, with neffy U.S. net product | May 15, 2026 |
| LIXT | PRESS-RELEASE | neutral | 3/10 | Lixte Biotechnology filed its Q1 2026 10-Q, reporting an EPS of -$0.27 with no consensus estimate available. The press r | May 14, 2026 |
| MDCX | PRESS-RELEASE | bearish | 6/10 | Medicus Pharma reported Q1 2026 results with a net loss of $9.0M (vs. $5.1M a year ago), cash of $6.4M, and disclosed su | May 14, 2026 |
| HCWB | PRESS-RELEASE | bearish | 7/10 | HCW Biologics reported Q1 2026 GAAP net income of $3.5M ($0.37 EPS), a dramatic swing from a $2.2M loss a year ago, driv | May 14, 2026 |
| EDSA | PRESS-RELEASE | neutral | 4/10 | Edesa Biotech reported Q2 2026 net loss of $4.2M ($0.49/share), wider than the $1.6M loss ($0.30/share) a year ago, as R | May 14, 2026 |
| DARE | PRESS-RELEASE | neutral | 5/10 | Daré Bioscience reported Q1 2026 EPS of -$0.20, a 60% beat vs the -$0.50 consensus, but this is a mechanical artifact of | May 14, 2026 |
| AARD | PRESS-RELEASE | bearish | 8/10 | Aardvark Therapeutics announced the FDA placed a full clinical hold on its IND for ARD-101, covering the Phase 3 HERO tr | May 14, 2026 |
| MNPR | PRESS-RELEASE | bullish | 6/10 | Monopar reported Q1 2026 EPS of -$0.46, beating consensus of -$0.90 by 48.9%, driven by lower-than-expected operating ex | May 14, 2026 |
| IXHL | PRESS-RELEASE | bullish | 6/10 | Incannex Healthcare announced the commencement of its DReAMzz clinical study for IHL-42X in obstructive sleep apnea, a c | May 14, 2026 |
| SLXN | PRESS-RELEASE | neutral | 4/10 | Silexion Therapeutics reported positive preclinical data showing its siRNA candidate SIL204 increases MHC-I expression i | May 14, 2026 |
| TOMZ | PRESS-RELEASE | bullish | 5/10 | TOMI Environmental Solutions announced a second SteraMist Hybrid System installation at a large East Coast research univ | May 14, 2026 |
| CURX | PRESS-RELEASE | neutral | 3/10 | Curanex Pharmaceuticals provided a Q1 2026 business update focused on preclinical progress for its lead candidate Phyto- | May 14, 2026 |
| SNTI | PRESS-RELEASE | bullish | 7/10 | Senti Bio reported Q1 2026 EPS of -$0.14, beating consensus of -$0.36 by 61%, on minimal revenue of $16K. The beat is dr | May 14, 2026 |
| AIM | PRESS-RELEASE | neutral | 4/10 | AIM ImmunoTech issued a press release highlighting a KOL segment discussing Ampligen for late-stage pancreatic cancer. T | May 14, 2026 |
| SNTI | PRESS-RELEASE | bullish | 8/10 | Senti Bio announced a successful Type B RMAT meeting with the FDA, finalizing a single-arm registrational trial strategy | May 14, 2026 |
| BIIB | PRESS-RELEASE | bullish | 7/10 | Biogen completed its acquisition of Apellis Pharmaceuticals for $41 per share in cash plus up to $4 per share in conting | May 14, 2026 |
| DWTX | PRESS-RELEASE | bullish | 6/10 | Dogwood Therapeutics reported Q1 2026 EPS of -$0.15, beating consensus of -$0.20 by 25%, with no revenue. The company hi | May 14, 2026 |
| CADL | PRESS-RELEASE | neutral | 5/10 | Candel Therapeutics reported Q1 2026 EPS of -$0.54, a 65.6% miss vs consensus of -$0.33, with no revenue. The company hi | May 14, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber appointed Peter M. O'Rourke Sr., former Acting Secretary of the VA and military veteran, as an independent | May 14, 2026 |
| CINGW | PRESS-RELEASE | neutral | 5/10 | Cingulate reported a net loss of $9.3M for Q1 2026, widening from $3.9M a year ago, driven by a surge in G&A expenses to | May 14, 2026 |
| CLNN | PRESS-RELEASE | bearish | 6/10 | Clene reported Q1 2026 EPS of -$0.69 (GAAP), a significant miss versus the -$0.50 consensus, driven by $6.0M in other ex | May 14, 2026 |
| SNYR | PRESS-RELEASE | bearish | 8/10 | Synergy CHC reported a disastrous Q1 2026: revenue collapsed 33% YoY to $5.49M (missing $8.3M consensus by 34%), EPS swu | May 14, 2026 |
| MGTX | PRESS-RELEASE | bullish | 7/10 | MeiraGTx reported Q1 2026 EPS of $0.19, a 142% beat vs consensus of -$0.45, on revenue of $0.3M (well below the $17.0M c | May 14, 2026 |
| BNTC | PRESS-RELEASE | bullish | 6/10 | Benitec Biopharma reported Q3 FY2026 (March 31, 2026) net loss of $0.24/share, beating consensus of -$0.28 by 5.5%. The | May 14, 2026 |
| CMMB | PRESS-RELEASE | neutral | 4/10 | Chemomab reported Q1 2026 net loss of $1.8M ($0.003/share) vs $3.3M in Q1 2025, with cash burn reduced to $2.4M. The com | May 14, 2026 |
| KROS | PRESS-RELEASE | bearish | 6/10 | Keros Therapeutics reported Q1 2026 EPS of -$1.21, a 31.5% miss vs consensus of -$0.92, and revenue of $0.367M, 78.4% be | May 14, 2026 |
| AGMB | PRESS-RELEASE | neutral | 2/10 | Agomab Therapeutics announced that management will participate in upcoming industry and investor conferences. This is a | May 14, 2026 |